Cooley Advises Intersect ENT on $63 Million Initial Public Offering

Palo Alto – July 31, 2014 – Cooley LLP announced today that it advised Intersect ENT, Inc. on its $63.3 million IPO. Intersect is a commercial drug-device company committed to improving the quality of life for patients with ear, nose and throat conditions. The company now trades on the NASDAQ Global Stock Market under the symbol "XENT."

The Cooley corporate securities team was comprised of partner Matthew Hemington, of counsel Brett White, and associates Seth Gottlieb, Matt Fleming and Daniel Elefant. Critical support for the offering was provided by partner Mark Windfeld-Hansen (tax); partner Renee Deming (compensation and benefits); partner Natasha Leskovsek, special counsel Phil Mitchell and associate Jennifer Shanley (health care and life sciences regulatory).

Thus far in 2014, Cooley has advised on 70 completed public offerings, including 35 completed IPOs.

About Cooley LLP

Cooley's attorneys solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and bet-the-company litigation, often where innovation meets the law.

Cooley has more than 750 lawyers across 11 offices in the United States and China.


Related Contacts
Matthew Hemington Partner, Palo Alto
Brett White Of Counsel, Palo Alto
Seth Gottlieb Partner, Palo Alto
Natasha Leskovsek Of Counsel, Washington, DC
Renee Deming Retired Partner, Palo Alto
Mark Windfeld-Hansen Partner, Palo Alto
Phil Mitchell Partner, New York